Compare Allegion PLC (ALLE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allegion PLC vs BIO-TECHNE Corp — how do they compare? Allegion PLC trades at $168.15 (market cap $14.08B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Allegion PLC is the larger of the two by market cap, and Allegion PLC pays the higher dividend (1.28%). Which is the better fit depends on your goals.
| ALLE | TECH | |
|---|---|---|
Market Cap | $14.08B | $11.24B |
Sector | Industrials | Health |
52-Week High | $179.77 | $72.29 |
52-Week Low | $125.65 | $43.31 |
Enterprise Value | $15.79B | $11.32B |
Dividend Yield | 1.28% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $168.94, up 0.14% today, near its consensus price target of $156. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent Q2 2026 earnings beat expectations with EPS of $2.40 and revenue growth of 13% year-over-year, driven by Americas segment strength. The company raised full-year guidance, reflecting robust demand in residential and non-residential markets.
Outlook remains positive due to earnings momentum and raised guidance, but risks include high valuation multiples and reliance on Americas growth. Analysts are mixed with 30% buy ratings; institutional buying supports confidence. Key resistance is at $171, with support at $167.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
